Targeted cholesterol-lowering therapy can prevent first heart attack or stroke in high-risk patients with diabetes
Mass General Brigham researchers found that the intensive cholesterol‑lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high‑risk patients who did not have known atherosclerosis (the…